Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatism

Volumn 52, Issue 1, 2005, Pages 27-35

  Quinn, Mark A ^a   Conaghan, Philip G ^a   O'Connor, Philip J ^a   Karim, Zunaid ^a   Greenstein, Adam ^a   Brown, Andrew ^a   Brown, Clare ^a   Fraser, Alexander ^a   Jarret, Stephen ^a   Emery, Paul ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BONE EROSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SYNOVITIS; VASCULITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; METHOTREXATE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SYNOVITIS;

EID: 19944431840     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20712     Document Type: Article

References (31)

1. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
2. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001;40:1211-20.
3. Emery P. Prognosis in inflammatory arthritis: the value of HLA genotyping and oncological analogy. J Rheumatol 1997;24: 1436-42.
4. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis [review]. Arthritis Rheum 2003;48: 1771-4.
5. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21 Suppl 31:S154-7.
6. Lipsky P, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-602.
7. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-93.
8. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
9. Baert FJ, d'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
10. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
11. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
12. Present DH, Rutgeerts P, Targan S, Hanauer SG, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340: 1398-405.
13. Buch M, Marzo-Ortega H, Bingham SJ, Lindsay S, Emery P. What happens when infliximab is stopped after two years exposure in patients with RA? Time taken to flare and efficacy on reintroduction of infliximab. Rheumatology (Oxford) 2004;43: 243-4.
14. Conaghan PG, O'Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003;48:64-71.
15. Ostergaard M, Hansen M, Stoltenberg M, Gideon P, Klarland M, Jensen KE, et al. Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. Arthritis Rheum 1999;42:918-29.
16. Ostergaard M, Hansen M, Stoltenberg M, Jensen KE, Szkudlarek M, Pederson-Zbinden B, et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum 2003;48:2128-31.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
19. Van der Heijde D. Plain x-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Ballieres Clin Rheumatol 1996;10:435-53.
20. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
21. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
22. De Jong Z, van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997; 36:878-83.
23. Stenger AA, van Leuewen zfnMA, Houtman PM, Bruyn GA, Speestra F, Barendsen BC, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
24. Van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, van de Putte LB, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis: towards development of a decision support system. J Rheumatol 1997;24:20-7.
25. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473-7.
26. Boers M, Kostense PJ, Verhoeven AC, van der Linden S, and the COBRA Trial Group. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum 2001;44:2242-6.
27. Fries JF, Williams CA, Morfield D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
28. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, et al. The acute phase and function in early RA: CRP levels correlate with functional outcome. J Rheumatol 1997;24:9-13.
29. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
30. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single drug-therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353:1568-73.
31. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedmaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.